RayzeBio

Defeating cancer with radiopharmaceutical medicines

Industry

Biotechnology Research

Headquarters

San Diego, CA

Company Size

75+ employees

Leader in targeted radiopharmaceuticals to improving cancer patient survival. Broad pipeline of innovative drugs against solid tumor targets.

News

RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors

RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)

Building career-spanning relationships, from candidacy to organizational leadership, we provide access to the future of the Medtech and Pharma.